Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCapital LeasesCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Artiva Biotherapeutics (ARTV) Non-Current Assets (2023 - 2025)

Historic Non-Current Assets for Artiva Biotherapeutics (ARTV) over the last 3 years, with Q3 2025 value amounting to $19.3 million.

  • Artiva Biotherapeutics' Non-Current Assets fell 7422.67% to $19.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $81.9 million, marking a year-over-year change of. This contributed to the annual value of $21.0 million for FY2024, which is 1717.08% down from last year.
  • Latest data reveals that Artiva Biotherapeutics reported Non-Current Assets of $19.3 million as of Q3 2025, which was down 7422.67% from $20.3 million recorded in Q2 2025.
  • Artiva Biotherapeutics' Non-Current Assets' 5-year high stood at $75.0 million during Q3 2024, with a 5-year trough of $19.3 million in Q3 2025.
  • Its 3-year average for Non-Current Assets is $29.8 million, with a median of $21.3 million in 2025.
  • Its Non-Current Assets has fluctuated over the past 5 years, first crashed by 1717.08% in 2024, then plummeted by 7422.67% in 2025.
  • Artiva Biotherapeutics' Non-Current Assets (Quarter) stood at $25.3 million in 2023, then dropped by 17.17% to $21.0 million in 2024, then decreased by 7.69% to $19.3 million in 2025.
  • Its Non-Current Assets stands at $19.3 million for Q3 2025, versus $20.3 million for Q2 2025 and $21.3 million for Q1 2025.